Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003661 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study of Lymphoma and Leukemia, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 17
- Study locations
NCT00003661 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 3 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 9 states.
The verdict
NCT00003661, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy, radiation therapy, and umbilical cord blood transplantation in treating patients who have hematologic cancer.
Conditions Studied
Interventions
- DRUG methylprednisolone
- DRUG melphalan
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Study Locations (17)
Florida
- University of Florida Health Science Center - Gainesville
- Division of Pediatric Surgery - Jacksonville
- Nemours Children's Clinic - Jacksonville
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
- North Shore University Hospital - Manhasset
- New York Blood Center - New York
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
North Carolina
- Lineberger Comprehensive Cancer Center, UNC - Chapel Hill
- Duke Comprehensive Cancer Center - Durham
South Carolina
- Medical University of South Carolina - Charleston
- University of South Carolina School of Medicine - Columbia
Louisiana
- Children's Hospital of New Orleans - New Orleans
Missouri
- Cardinal Glennon Children's Hospital - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 1998-06 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003661
The ClinicalTrials.gov registry entry for NCT00003661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which methylprednisolone is the first listed.
NCT00003661 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Florida, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT00003661 about?
NCT00003661 is a clinical study titled "Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy....
What is the current status of trial NCT00003661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 1998-06. Estimated completion is 2006-03.
What conditions does trial NCT00003661 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Neuroblastoma, Graft-Versus-Host Disease.
What interventions are being tested in trial NCT00003661?
The interventions under investigation include: methylprednisolone (DRUG), melphalan (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003661?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003661 being conducted?
This trial has 17 study locations across Florida, Illinois, Louisiana, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.